Critical Analysis: XBiotech (XBIT) & Its Rivals
XBiotech (NASDAQ: XBIT) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare XBiotech to related businesses based on the strength of its earnings, risk, analyst recommendations, profitability, dividends, institutional ownership and valuation.
Insider and Institutional Ownership
11.0% of XBiotech shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 35.7% of XBiotech shares are owned by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of current ratings for XBiotech and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
XBiotech presently has a consensus target price of $13.00, indicating a potential upside of 178.97%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.59%. Given XBiotech’s higher probable upside, research analysts plainly believe XBiotech is more favorable than its competitors.
Valuation & Earnings
This table compares XBiotech and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|XBiotech Competitors||$284.28 million||$33.78 million||72.78|
XBiotech’s competitors have higher revenue and earnings than XBiotech. XBiotech is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
XBiotech has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500. Comparatively, XBiotech’s competitors have a beta of 5.99, suggesting that their average stock price is 499% more volatile than the S&P 500.
This table compares XBiotech and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
XBiotech competitors beat XBiotech on 8 of the 12 factors compared.
XBiotech Company Profile
XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system. Xilonix is a therapeutic antibody, which specifically neutralizes interleukin-1 alpha (IL-1a). Its pipeline includes various human antibodies for treating diseases, such as cancer, vascular disease, inflammatory skin disease and diabetes. The Company has completed a Phase III study in Europe for the treatment of symptomatic colorectal cancer. It also investigated its lead product candidate in clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS).
Receive News & Ratings for XBiotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.